Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

InnoCare Starts China Trial of SHP2 Inhibitor for Solid Tumors

publication date: Jun 22, 2022

Beijing InnoCare has dosed the first patient in a China clinical trial of its novel SHP2 allosteric inhibitor in patients with solid tumors. SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) is involved in mediating the MAPK signaling pathway and immune checkpoint pathway, regulating cellular proliferation and survival. In preclinical studies, the candidate, ICP-189, showed better selectivity than other phosphatases and produced significant anti-tumor effects in various xenograft models, according to InnoCare. Founded in 2015, InnoCare is developing novel drugs for cancer and autoimmune diseases. More details....

Stock Symbol: (HK: 09969)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022